SRA
DAWN

Summit Rock Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Summit Rock Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-51,502
Closed -$851K – 9
2024
Q1 		$851K Buy
+51,502
New +$771K 0.27% 9
2022
Q4 		– Sell
-25,751
Closed -$516K – 3
2022
Q3 		$516K Sell
25,751
-7,374
-22% -$157K 0.4% 5
2022
Q2 		$593K Hold
33,125
– – 0.48% 5
2022
Q1 		$329K Hold
33,125
– – 0.2% 7
2021
Q4 		$558K Buy
+33,125
New +$681K 0.33% 6

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Summit Rock Advisors's DAWN Position: Q2 2024 in Review

Summit Rock Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q2 2024, closing a stake of 51,502 shares — an estimated $851K sold.

Summit Rock Advisors first reported a position in DAWN in Q4 2021 and held it in 5 quarters. The position peaked at $851K in Q1 2024. 156 funds tracked by Wall St. Rank hold DAWN as of Q2 2024.

  • Summit Rock Advisors reported no remaining Day One Biopharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Summit Rock Advisors sold 51,502 Day One Biopharmaceuticals shares in Q2 2024, an estimated $851K.
  • Summit Rock Advisors first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Summit Rock Advisors's Day One Biopharmaceuticals position peaked at $851K in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2024.

Based on Summit Rock Advisors's 13F filing for Q2 2024, filed 25 Jul 2024.